Estrogen alters amyloid precursor protein as well as dendritic and cholinergic markers in a mouse model of down syndrome

Hippocampus

Volumn 13, Issue 8, 2003, Pages 905-914

  Granholm, Ann Charlotte ^a   Sanders, Linda ^b   Seo, Hyemyung ^c,d   Lin, Ling ^c,d   Ford, Kerstin ^e   Isacson, Ole ^c,d  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c MCLEAN HOSPITAL   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

Author keywords

Acetylcholine; Alzheimer's disease; Amyloid precursor protein; Amyloid peptide; Cortex; Dementia; Down syndrome; Hippocampus; Microtubule associated proteins; Neuro degeneration

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID PRECURSOR PROTEIN; BIOLOGICAL MARKER; BRAIN PROTEIN; CELL MARKER; ESTRADIOL; ESTROGEN; MICROTUBULE ASSOCIATED PROTEIN; MICROTUBULE ASSOCIATED PROTEIN 2; NEUROPROTECTIVE AGENT;

AGE; ALZHEIMER DISEASE; AMNESIA; ANIMAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; BRAIN REGION; CELL DENSITY; CHOLINERGIC NERVE; CHOLINERGIC NERVE CELL; CHROMOSOME STRUCTURE; CONTROLLED STUDY; CORPUS STRIATUM; DEMENTIA; DENDRITE; DENDRITIC CELL; DISEASE MODEL; DOWN SYNDROME; DRUG EFFECT; DRUG PELLET; EARLY MENOPAUSE; ESTROGEN THERAPY; FEMALE; GENETICS; HIPPOCAMPUS; HISTOCHEMISTRY; HORMONE DETERMINATION; IMMUNOHISTOCHEMISTRY; METABOLISM; MOUSE; MOUSE MUTANT; NEURITE; NONHUMAN; ONSET AGE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PRIORITY JOURNAL; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; TRISOMY; TRISOMY 16; UPREGULATION;

ACETYLCHOLINESTERASE; AGE FACTORS; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BIOLOGICAL MARKERS; BRAIN CHEMISTRY; CHOLINERGIC FIBERS; CORPUS STRIATUM; DENDRITES; DISEASE MODELS, ANIMAL; DOWN SYNDROME; ESTROGENS; FEMALE; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NEUROLOGIC MUTANTS; MICROTUBULE-ASSOCIATED PROTEINS; NEUROPROTECTIVE AGENTS; TRISOMY; UP-REGULATION;

EID: 0345874735     PISSN: 10509631     EISSN: None     Source Type: Journal    
DOI: 10.1002/hipo.10130     Document Type: Article

References (85)

1. Adlard PA, King CE, Vickers JC. 2000. The effects of taxol on the central nervous system response to physical injury. Acta Neuropathol (Berl) 100:183-188.
2. Archer TK, Fryer CJ, Lee HL, Zaniewski E, Liang T, Mymryk JS. 1995. Steroid hormone receptor status defines the MMTV promoter chromatin structure in vivo. J Steroid Biochem Mol Biol 53:421-429.
3. Ashford JW, Soultanian NS, Zhang SX, Geddes JW. 1998. Neuropil threads are collinear with Map 2 immunostaining in neuronal dendrites of Alzheimer brain. J Neuropathol Exp Neurol 57:972-978.
4. Backman C, Rose GM, Hoffer BJ, Henry MA, Bartus RT, Friden P, Granholm A-C. 1996. Systemic administration of a nerve growth factor conjugate reverses age-related cognitive dysfunction and prevents cholinergic neuron atrophy. J Neurosci 16:5437-5442.
5. Behl c, Moosman B, Manthey D, Heck S. 2000. The female sex hormone estrogen as neuroprotectant: activities at various levels. In: Neuronal and cognitive effects of estrogen. Novartis Foundation Symposium 230. Chichester: Wiley. p 221-238.
6. Bimonte HA, Denenberg VH. 1999. Estradiol facilitates performance as working memory load increases. Psychoneuroendocrinology 24:161-173.
7. Bimonte HA, Hunter CL, Nelson ME, Granholm A-C. 2002a. Frontal cortex BDNF levels correlate with working memory in an animal model of Down syndrome. Behav Brain Res 189:47-87.
8. Bimonte HA, Granholm A-C, Seo H, Isacson O. 2002b. Spatial memory testing decreases hippocampal APP in young, but not aged, female rats. Neurosci Lett 298:50-54.
9. Birge S. 1996. Is there a role for estrogen treatment therapy in the prevention and treatment of dementia? J Am Gerontol Soc 44:865-870.
10. Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. 2000. Tau protein isoforms, phosphorylation and role in neurodegenerative disease. Brain Res Brain Res Rev 33:95-130.
11. Carr J, Hollins S. 199 5. Menopause in women with learning disabilities. J Intell Disabil Res 39:137-139.
12. Casanova MF, Walker LC, Whitehouse PJ, Price DL. 1985. Abnormalities of the nucleus basalis in Down's syndrome. Ann Neurol 18:310-313.
13. Chang D, Kwan J, Timiras PS. 1997. Estrogens influence growth, maturation, and amyloid β-peptide production in neuroblastoma cells and in a β-APP transfected kidney 293 cell line. Adv Exp Med Biol 23: 261-271.
14. Chao HM, Spencer RL, Frankfurt M, McEwen BS. 1994. The effects of aging and hormonal manipulation on Amyloid precursor protein APP695 mRNA expression in the rat hippocampus. J Neuroendocrinol 6:517-521.
15. Cooper JD, Salehi A, Delcroix JD, Howe CL Belichenko PV, Chua-Couzens J, Kilbridge JF, Carlson EJ, Epstein CJ, Mobley WC. 2001. Failed retrograde transport of NGF in a mouse model of Down's syndrome: reversal of cholinergic degenerative phenotypes following NGF infusion. Proc Natl Acad Sci USA 98:10439-10444.
16. Cordoba Montoya DA, Carrer HF. 1997. Estrogen facilitates induction of long term potentiation in the hippocampus of awake rats. Brain Res 778:430-438.
17. Cosgrave MP, Tyrrell J, McCarron M, Gill M, Lawlor BA. 1999. Age at onset of dementia and age of menopause in women with Down's syndrome. J Intell Disabil Res 43:461-465.
18. Costa ACS, Walsh K, Davisson MT. 1999. Motor dysfunction in a mouse model of Down syndrome. Phys Behav 68:211-220.
19. Crnic LS, Pennington BF. 2000. Contributions of mouse models to understanding Down syndrome. Prog Infancy Res 1:69-111.
20. Cummings JL, Vinters HV, Cole GM, Khachaturian ZS. 1998. Alzheimer's disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurology 51 (suppl):S2-S17.
21. Daniel JM, Fader AJ, Spencer AL, Dohanich GP. 1997. Estrogen enhances performance of female rats during acquisition of a radial arm maze. Horm Behav 32:217-225.
22. Davisson MT, Schmidt C, Akeson EC. 1990. Segmental trisomy of murine chromosome 16: a new model system for studying Down syndrome. Prog Clin Biol Res 360:263-280.
23. Demas GE, Nelson RJ, Krueger BK, Yarowsky PJ. 1996. Spatial memory deficits in segmental trisomic Ts65Dn mice. Behav Brain Res 82:85-92.
24. Demas GE, Nelson RJ, Krueger BK, Yarowsky PJ. 1998. Impaired spatial working and reference memory in segmental trisomy (Ts65Dn) mice. Behav Brain Res 90:199-201.
25. Fader AJ, Johnson PEM, Dohanich GP. 1999. Estrogen improves working but not reference memory and prevents amnestic effects of scopolamine on a radial arm maze. Pharm Biochem Behav 62:711-717.
26. Gandy S, Duff K. 2000. Post-menopausal estrogen deprivation and Alzheimer's disease. Exp Gerontol 35:503-511.
27. Garcia ML, Cleveland DW. 2001. Going new places using an old MAP: tau, microtubules, and human neurodegenerative disease. Curr Opin Cell Biol 13:41-48.
28. Geddes JW, Bondada V, Keller JN. 1994. Effects of intrahippocampal colchicine administration on the levels and localization of microtubule-associated proteins, tau and Map 2. Brain Res 633:1-8.
29. Gibbs RB. 1998. Impairment of basal forebrain cholinergic neurons associated with aging and long-term loss of ovarian function. Exp Neurol 151:289-302.
30. Granholm A-C, Sanders LA, Crnic LS. 2000. Loss of cholinergic phenotype in basal forebrain coincides with cognitive decline in a mouse model of Down's syndrome. Exp Neurol 161:647-663.
31. Granholm A-C, Ford KA, Hyde LA, Bimonte HA, Hunter CL, Nelson M, Albeck DS, Sanders LA, Mufson EJ, Crnic LS. 2002. Estrogen restores cognition and cholinergic phenotype in an animal model of Down syndrome. Physiol Behav 77:371-385.
32. Grasso P, Reichert LE Jr. 1996. In vivo effects of follicle-stimulating hormone-related synthetic peptides on the mouse estrous cycle. Endocrinology 137:5370-5375.
33. Haass C, Koo E, Mellon A, Jung A, Selkoe D. 1992. Targeting of cell-surface β-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. Nature 357:500-503.
34. Head E, Azizeh BY, Lott IT, Tenner AJ, Cotman CW, Cribbs DH. 2001. Complement association with neurons and β-amyloid deposition in the brains of aged individuals with Down's syndrome. Neurobiol Dis 8:252-265.
35. Henderson VW, Paganini-Hill A, Emanuel CK, Dunn ME, Buckwalter JG. 1994. Estrogen replacement therapy in older women. Comparisons between Alzheimer's disease cases and nondemented control subjects. Arch Neurol 51:896-900.
36. Holtzman DM, Kilbridge J, Chen KS, Rabin J, Luche R, Carlson EJ, Epstein EJ, Mobley WC. 1995. Preliminary characterization of the central nervous system in partial trisomy 16 mice. Prog Clin Biol Res. 393:227-240.
37. Holtzman DM, Santucci D, Kilbridge J, Chua-Couzens J, Fontana DJ, Daniels SE, Johnson RM, Chen K, Sun Y, Carlson E, Alleva E, Epstein CJ, Mobley WC. 1996. Developmental abnormalities and age-related neurodegencration in a mouse model of Down syndrome. Proc Natl Acad Sci USA 93:13333-13338.
38. Hunter CL, Bimonte HA, Granholm A-C. 2003. Behavioral comparison of four and six month-old Ts65Dn mice: age-related impairments in working and reference memory. Behav Brain Res 138:121-131.
39. Hyde LA, Pollock A, Bickford PC, Crnic LS. 2001a. Motor learning in trisomic mice, a model for Down syndrome. Dev Psychobiol 38:33-45.
40. Hyde LA, Frisone DF, Crnic LS. 2001b. Trisomic mice, a model for Down syndrome, have deficits in context discrimination learning suggesting impaired hippocampal function. Behav Brain Res 118:53-60.
41. Inestrosa NC, Marzolo MP, Bonnefont AB. 1998. Cellular and molecular basis of estrogen's neuroprotection. Potential relevance for Alzheimer's disease. Mol Neurobiol 17:73-86.
42. Isacson O, Seo H, Lin L, Albeck DA, Granholm A-C. 2002. Alzheimer's disease and Downs syndrome: roles of APP, trophic factors and ACh. TINS 25:79-84.
43. Isgor C, Sengelaub DR. 1998. Prenatal gonadal steroids affect adult spatial behavior, CA1 and CA3 pyramidal cell morphology in rats. Horm Behav 34:183-198.
44. Jaffe AB, Torand-Allerand CD, Greengard P, Gandy SE. 1994. Estrogen regulates metabolism of Alzheimer amyloid beta precursor protein. J Biol Chem 269:13065-13068.
45. Jellinger K, Braak H, Braak E, Fischer P. 1991. Alzheimer lesions in the entorhinal region and isocortex in Parkinson's and Alzheimer's disease. Ann NY Acad Sci 640:203-209.
46. Kamal A, Stokin GB, Yang Z, Xia CH, Goldstein LS. 2000. Axonal transport of amyloid precursor protein is mediated by direct binding to the kinesin light chain subunit kinesin-1. Neuron 28:449-459.
47. Kasa P, Rakonczay Z, Gulya K. 1997. The cholinergic system in Alzheimer's disease. Prog Neurobiol 52:511-535.
48. Klein SL, Kriegsfield LJ, Hairston JE, Rau V, Nelson RJ, Yarowsky PJ. 1996. Characterization of sensorimotor performance, reproductive and aggressive behaviors in segmental trisomic 16 (Trisomic) mice. Physiol Behav 60:1159-1164.
49. Korenberg JR, Chen X-N, Devon KL, Noya D, Oster-Granite ML, Birren BW. 1999. Mouse molecular cytogenetic resource: 157 BACs link the chromosomal and genetic maps. Genome Res 9:514-523.
50. Lawrence AD, Sahakian BJ. 1998. The cognitive psychopharmacology of Alzheimer's disease: focus on cholinergic systems. Neurochem Res 23:787-794.
51. Leverenz JB, Raskind MA. 1998. Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis. Exp Neurol 150:296-304.
52. Lin L, LeBlanc CJ, Deacon TW, Isacson O. 1998. Chronic cognitive deficits and amyloid precursor protein elevation after immunotoxin lesions of the basal forebrain cholinergic system. NeuroReport 9:547-552.
53. Lin L, Georgievska B, Mattsson A, Isacson O. 1999. Cognitive changes and modified processing of amyloid precursor protein in the cortical hippocampal system after cholinergic synapse loss and muscarinic receptor activation. Proc Natl Acad Sci USA 96:12108-12113.
54. Luine VN, Richards ST, Wu VY, Beck KD. 1998. Estradiol enhances learning and memory in a spatial memory task and effects levels of monoaminergic neurotransmitters. Horm Behav 34:149-162.
55. Mann DM, Esiri MM. 1989. The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome. J Neurol Sci 89:169-179.
56. Mattson MP, Guo ZH, Geiger JD. 1999. Secreted form of amyloid precursor protein enhances basal glucose and glutamate transport and protects against oxidative impairment of glucose and glutamate transport in synaptosomes by a cyclic GMP-mediated mechanism. J Neurochem 73:532-537.
57. McEwen BS, Alves SE, Bulloch K, Weiland NG. 1997. Ovarian steroids and the brain: implications for cognition and aging. Neurology 48(suppl 7):S8-S15.
58. Mileusnic R, Lancashire CL, Johnston AN, Rose S. 2000. App is required during an early phase of memory formation. Eur J. Neurosci 12:4487-4495.
59. Mukaetova-Ladinska EB, Garcia-Siera F, Hurt J, Gertz HJ, Xuereb JH, Brayne C, Huppert FA, Paykel ES, McGee M, Jakes R, Honer WG, Harrington CR, Wischik CM. 2000. Staging of cytoskeletal and beta-amyloid changes in human isocortex reveals a biphasic synaptic protein response during progression of Alzheimer's disease. Am J Pathol 157: 623-536.
60. Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R, Koss E, Pfeiffer E, Jin S, Gamst A, Grundman M, Thomas R, Thal LJ. 2000. Estrogen replacement therapy for treatment of mild to moderate Alzheimer's disease. JAMA 283:1007-1115.
61. Neve R, McPhie DL, Chen Y. 2000. Alzheimer's disease: a dysfunction of the amyloid precursor protein. Brain Res 886:54-66.
62. Packard MG, Teather IA. 1997. Intra-hippocampal estradiol infusion enhances memory in ovariectornized rats. NeuroReport 8:3009-3013.
63. Patel BN, Seltzer GB, Wu H-S, Schupf N. 2001. Effect of menopause on cognitive performance in women with Down syndrome. Cogn Neurosci Neuropsychol 12:2659-2662.
64. Perez RG, Zheng H, Van der Ploeg LHT, Koo EH. 1997. The β-amyloid precursor protein of Alzheimer's disease enhances neuron viability and modulates neuronal polarity. J Neurosci 17:9407-9414.
65. Perry EK, Tomlinson BE, Blessed G, Perry RH, Cross AJ, Crow TJ. 1978. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ 2:1457-1459.
66. Petronis A. 1999. Alzheimer's disease and Down syndrome: from meiosis to dementia. Exp Neurol 158:403-413.
67. Price DL. 1999. New order from neurological disorders. Nature 399(suppl):A3-A5.
68. Reeves RH, Irving NG, Moran TH, Wohn Q, Kitt C, Sisodia SS, Schmidt C, Bronson RT, Davisson MT. 1995. A mouse model for Down syndrome exhibits learning and behavioral deficits. Nature Genet 11: 177-184.
69. Seabrook GR, Smith DW, Bowery BJ, Easter A, Reynolds T, Fitzjohn SM, Morton RA, Zheng H, Dawson GR, Sirinathsinghji DJ, Davies CH, Collingridge GL, Hill RG. 1999. Mechanisms contributing to the deficits in hippocampal synaptic plasticity in mice lacking amyloid precursor protein. Neuropharmacology 38:349-359.
70. Schneider LS, Farlow MK, Henderson VW, Pogodal JM. 1995. Estrogen replacement therapy may enhance response to tacrine in women with Alzheimer's disease. Neurology 45(suppl):A288.
71. Schupf N, Zigman W, Kapell D, Lee JH, Kline J, Levin B. 1997. Early menopause in women with Down's syndrome. J Intell Disabil Res 41:264-267.
72. Scott SA, Mufson EJ, Weingartner JA, Skau KA, Crotchet KA. 1995. Nerve growth factor in Alzheimer's disease: increased levels through-out the brain coupled with declines in nucleus basalis. J Neurosci 15:6213-6221.
73. Selkoe DJ. 1999. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 399(suppl):A23-A31.
74. Sendera TJ, Ma SY, Jaffar S, Kozlowski PB, Kordower JH, Mawal Y, Saragovi HU, Mufson EJ. 2000. Reduction in trkA immunoreactive neurons is not associated with an overexpression of galaninergic fibers within the nucleus basalis in Down's syndrome. J Neurochem 74: 1185-1196.
75. Shi J, Panickar KS, Yang SH, Rabbani O, Day AL, Simpkins JW. 1998. Estrogen attenuates over-expression of beta-amyloid precursor protein messenger RNA in an animal model of focal ischemia. Brain Res 810: 87-92.
76. Simpkins JW, Green PS, Gridley KE, Singh M, de Fiebre NC, Rajakumar G. 1997. Role of estrogen replacement therapy in memory enhancement and the prevention of neuronal loss associated with Alzheimer's disease. Am J Med 103:19S-25S.
77. Tanapat P, Hastings NB, Reeves AJ, Gould E. 1999. Estrogen stimulates a transient increase in the number of new neurons in the dentate gyrus of the adult female rat. J Neurosci 19:5792-5801.
78. Tang M-X, Jacobs D, Stern Y, Marder K, Schofield P, Gotland B, Andrews H, Mayeux R. 1996. Effect of oestrogen during menopause on risk and age of onset of Alzheimer's disease. Lancet 348:429-432.
79. Veinbergs I, Mallory M, Sagara Y, Masliah E. 2000. Vitamin E supplementation prevents spatial learning deficits and dendritic alterations in aged apolipoprotein E-deficient mice. Eur J Neurosci 12:4541-4546.
80. Watson MA, Milbrandt TJ. 1989. The NGFI-β gene, a transcriptionally inducible member of the steroid receptor gene superfamily: genomic structure and expression in rat brain after seizure induction. Mol Cell Biol 9:4213-4219.
81. Whitehouse PJ. 1998. The cholinergic deficit in Alzheimer's disease. J Clin Psychiatry 59(suppl 13):19-22.
82. Wisniewski KE, Wisniewski HM, Wen GY. 1985. Occurrence of neuropathological changes and dementia of Alzheimer's disease and Down's syndrome. Ann Neurol 17:278-282.
83. Woolley CS, McEwen BS. 1992. Estradiol mediates fluctuation in hippocampal synapse density during the estrous cycle in the adult rat. J Neurosci 12:2549-2554.
84. Xu H, Gouras GK, Greenfield JP. 1998. Estrogen reduces neuronal generation of Alzheimer β-amyloid peptides. Nature Med 4:447-451.
85. Yates CM, Simpson J, Maloney AF, Gordon A, Reid AH. 1980. Alzheimer-like cholinergic deficiency in Down syndrome [letter]. Lancet 2:979.